M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
The impact of response on bone-directed therapy in patients with multiple myeloma
Alessandra Larocca,J. Anthony Child,Gordon Cook,Graham Jackson,Nigel H. Russell,AJ Szubert,Walter M Gregory,Annamaria Brioli,Roger G. Owen,Mark T. Drayson,Ping Wu,Antonio Palumbo,Mario Boccadoro,Faith E. Davies,Gareth J. Morgan +14 more
TL;DR: Analysis of Myeloma IX data indicates that response category posttransplant may influence the impact of bisphosphonate therapy, and zoledronic acid was associated with a significant benefit in patients in PR.
Journal ArticleDOI
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
Candida Vitale,Maria Chiara Montalbano,Chiara Salvetti,Elia Boccellato,Valentina Griggio,Mario Boccadoro,Marta Coscia +6 more
TL;DR: Currently available data concerning autoimmune phenomena in patients with CLL is reviewed, particularly focusing on patients treated with ibrutinib, idelalisib, or venetoclax, and the possible role of these agents in the management of AIC is discussed.
Journal ArticleDOI
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Sara Bringhen,Mattia D'Agostino,L De Paoli,Vittorio Montefusco,Anna Marina Liberati,P. Galieni,Sara Grammatico,Ve Muccio,Fabrizio Esma,C De Angelis,Pellegrino Musto,Stelvio Ballanti,Massimo Offidani,Maria Teresa Petrucci,Gianluca Gaidano,Paolo Corradini,Antonio Palumbo,Pieter Sonneveld,Mario Boccadoro +18 more
TL;DR: This first study of weekly carfilzomib plus an alkylating agent in elderly patients with NDMM was effective, with an acceptable risk/benefit ratio, and thus can be a valid option in this setting.
Journal ArticleDOI
Primary plasma cell leukemia in the era of new drugs: has something changed?
Pellegrino Musto,Livio Pagano,Maria Teresa Petrucci,Fortunato Morabito,Tommaso Caravita,Francesco Di Raimondo,Luca Baldini,Patrizia Tosi,Sara Bringhen,Massimo Offidani,Paola Omedè,Antonino Neri,Fiorella D'Auria,Giovanni Battista Bochicchio,Michele Cavo,Mario Boccadoro,Antonio Palumbo +16 more
TL;DR: An updated literature analysis about the current therapeutic scenario of PPCL is reported, with a particular focus on the use of novel agents.
Journal ArticleDOI
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Antonio Palumbo,Ilaria Avonto,Benedetto Bruno,Antonietta Falcone,Potito Rosario Scalzulli,Maria Teresa Ambrosini,Sara Bringhen,Cecilia Rus,Federica Cavallo,Patrizia Falco,Massimo Massaia,Pellegrino Musto,Mario Boccadoro +12 more
TL;DR: Melphalan/bortezomib/thalidomide/dexamethasone showed encouraging antimyeloma activity in patients with advanced-stage myeloma.